Table 2 Motor and balance change between baseline and follow-ups in the explorative and validation datasets.

From: Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease

 

Explorative set (n = 261)

Validation set (n = 111)

 

M1

Change to M0

M1

Change to M0

M12

Change to M0

M1 vs. M12

UPDRS-III (OFF)

32.1 ± 14.5

36.8 ± 27.4%a

34.2 ± 14.5

34.7 ± 27.4%a

31.7 ± 15.6

37.1 ± 37.5%a

p = 0.138

BBS (OFF)

46.2 ± 8.6

14.8 ± 21.9%a

47.1 ± 7.4

13.3 ± 21.3%a

46.8 ± 8.0

13.1 ± 25.4%a

p = 0.361

PT (OFF)b

1.1 ± 0.8

0.8 ± 1.0a

1.0 ± 0.9

0.8 ± 1.1a

1.1 ± 0.9

0.7 ± 1.0a

p = 0.729

UPDRS-III (ON)

19.4 ± 11.2

25.1 ± 33.7%a

21.2 ± 10.1

21.4 ± 33.7%a

19.6 ± 10.1

25.7 ± 37.6%a

p = 0.077

BBS (ON)

50.6 ± 7.4

1.3 ± 20.8%

51.5 ± 5.5

2.5 ± 8.7%

50.4 ± 8.8

1.4 ± 11.3%

p = 0.108

PT (ON)b

0.7 ± 1.0

0.2 ± 0.9

0.6 ± 0.9

0.2 ± 0.8

0.8 ± 0.8

-0.1 ± 1.0

p = 0.133

  1. aSignificant comparison between M1/M12 and M0, p < 0.01. Using either paired t-test or Wilcoxon signed-rank test.
  2. bChange values were presented as mean difference. Comparisons were conducted using Wilcoxon signed-rank test.
  3. Unindicated comparisons were conducted using paired t-test. Significant comparisons are marked in bold.
  4. M0 baseline value, M1 1-month follow-up, M12 12-month follow-up, OFF off medication, ON on medication, BBS Berg balance scale, PT pull test.
Back to article page